A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer

by | Jan 28, 2026 | Clinical Trials | 0 comments

​ Conditions: Advanced Gastric Cancer

Interventions: Drug: Trifluridine/Tipiracil (TAS-102) combined with Apatinib

Sponsors: Anhui Provincial Cancer Hospital

Not yet recruiting Conditions: Advanced Gastric Cancer
Interventions: Drug: Trifluridine/Tipiracil (TAS-102) combined with Apatinib
Sponsors: Anhui Provincial Cancer Hospital
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *